Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET

JOURNAL OF HEPATOLOGY

卷:69

Article

Liu, Jacey J.^1,2  Li, Yanjie^1,2,3  Chen, Wendy S.^1,2  Liang, Yan^1,2  Wang, Gaowei^1,2  Zong, Min^1,2  Kaneko, Kota^1,2  Xu, Ruiyun³  Karin, Michael^4,5  Feng, Gen-Sheng^1,2 

[1] Univ Calif San Diego, Dept Pathol, Moores UCSD Canc Ctr, La Jolla, CA 92093 USA

[2] Univ Calif San Diego, Div Biol Sci, Moores UCSD Canc Ctr, La Jolla, CA 92093 USA

[3] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepatobiliary Surg, Guangzhou, Guangdong, Peoples R China

[4] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA

[5] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA

关键词: Liver tumorigenesis;    Shp2;    Met;    beta-Catenin;    PIK3CA;   

DOI  :  10.1016/j.jhep.2018.02.014

来源: Elsevier

【 摘 要 】

Background & Aims: Shp2 is an SH2-tyrosine phosphatase acting downstream of receptor tyrosine kinases (RTKs). Most recent data demonstrated a liver tumor-suppressing role for Shp2, as ablating Shp2 in hepatocytes aggravated hepatocellular carcinoma (HCC) induced by chemical carcinogens or Pten loss. We further investigated the effect of Shp2 deficiency on liver tumorigenesis driven by classical oncoproteins c-Met (receptor for HGF), beta-catenin and PIK3CA. Methods: We performed hydrodynamic tail vein injection of two pairs of plasmids expressing c-Met and DN90-beta-catenin (MET/CAT), or c-Met and PIK3CAH1047R (MET/PIK), into WT and Shp2(hep-/-) mice. We compared liver tumor loads and investigated the pathogenesis and molecular mechanisms involved using multidisciplinary approaches. Results: Despite the induction of oxidative and metabolic stresses, Shp2 deletion in hepatocytes suppressed hepatocarcinogenesis driven by overexpression of oncoproteins MET/CAT or MET/PIK. Shp2 loss inhibited proliferative signaling from c-Met, Wnt/beta-catenin, Ras/Erk and PI3K/Akt pathways, but triggered cell senescence following exogenous expression of the oncogenes. Conclusions: Shp2, acting downstream of RTKs, is positively required for hepatocyte-intrinsic tumorigenic signaling from these oncoproteins, even if Shp2 deficiency induces a tumor-promoting hepatic microenvironment. These data suggest a new and more effective therapeutic strategy for HCCs driven by oncogenic RTKs and other upstream molecules, by inhibiting Shp2 and also suppressing any tumor-enhancing stromal factors produced because of Shp2 inhibition. Lay summary: Primary liver cancer is a malignant disease with poor prognosis, largely because there are limited systemic therapies available. We show here that a cytoplasmic tyrosine phosphatase Shp2 is required for liver tumorigenesis. This tumorigenesis is driven by two oncoproteins that are implicated in human liver cancer. This, together with our previous studies, uncovers the complexity of liver tumorigenesis, by elucidating the pro-and anti-tumor effects of Shp2 in mouse models. This data can be used to guide new therapies. (C) 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

【 授权许可】

Free